Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 1:344:e900.
doi: 10.1136/bmj.e900.

Screening and cervical cancer cure: population based cohort study

Bengt Andrae  1 , Therese M-L Andersson, Paul C Lambert, Levent Kemetli, Lena Silfverdal, Björn Strander, Walter Ryd, Joakim Dillner, Sven Törnberg, Pär Sparén
Affiliations

Screening and cervical cancer cure: population based cohort study

Bengt Andrae et al. BMJ. .

Abstract

Objective: To determine whether detection of invasive cervical cancer by screening results in better prognosis or merely increases the lead time until death.

Design: Nationwide population based cohort study.

Setting: Sweden.

Participants: All 1230 women with cervical cancer diagnosed during 1999-2001 in Sweden prospectively followed up for an average of 8.5 years.

Main outcome measures: Cure proportions and five year relative survival ratios, stratified by screening history, mode of detection, age, histopathological type, and FIGO (International Federation of Gynecology and Obstetrics) stage.

Results: In the screening ages, the cure proportion for women with screen detected invasive cancer was 92% (95% confidence interval 75% to 98%) and for symptomatic women was 66% (62% to 70%), a statistically significant difference in cure of 26% (16% to 36%). Among symptomatic women, the cure proportion was significantly higher for those who had been screened according to recommendations (interval cancers) than among those overdue for screening: difference in cure 14% (95% confidence interval 6% to 23%). Cure proportions were similar for all histopathological types except small cell carcinomas and were closely related to FIGO stage. A significantly higher cure proportion for screen detected cancers remained after adjustment for stage at diagnosis (difference 15%, 7% to 22%).

Conclusions: Screening is associated with improved cure of cervical cancer. Confounding cannot be ruled out, but the effect was not attributable to lead time bias and was larger than what is reflected by down-staging. Evaluations of screening programmes should consider the assessment of cure proportions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Definition of mode of detection and screening history based on time since latest smear test.* Result of smear tests taken without clinical suspicion do not lead to diagnosis of invasive cancer in less than one month. †Smear tests taken less than six months before diagnosis cannot have prevented invasive cancer but are considered, after referral and biopsy, to lead to diagnosis of a prevalent cancer
None
Fig 2 Relative survival ratios of cervical cancer (all histological types) for women of all ages, by screening history and mode of detection
None
Fig 3 Relative survival ratios of cervical cancer for women of all ages, by histological type
None
Fig 4 Relative survival ratios of cervical cancer (all histological types) for women of all ages, by FIGO stage
See this image and copyright information in PMC

Comment in

References

    1. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008;100:622-9. - PubMed
    1. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968. - PMC - PubMed
    1. Van der Aa MA, Schutter EM, Looijen-Salamon M, Martens JE, Siesling S. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of the Netherlands, 1992-2001. Eur J Obstet Gynecol Reprod Biol 2008;139:204-9. - PubMed
    1. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543. - PMC - PubMed
    1. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539. - PMC - PubMed

Publication types

MeSH terms